ArticleMetabolic engineering communications2026
Experimental and computational analysis of glycan processing at increased monoclonal antibody productivities.
Article in Metabolic engineering communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Optimization of cell culture conditions is critically important for successful commercial production of therapeutic antibodies; however, improvements in productivity may be offset by changes in critical quality attributes. We assessed the impact of two different process conditions (high and low yield) on growth, productivity, and glycan distribution for two CHO-S clones producing adalimumab, clone 1 (DHFR clone) and clone 2 (GS clone) in fed-batch shake flask cultures. High-yield cultures showed approximately 1.6-fold and 7.4-fold increases in integral of viable cells (IVC) for clones 1 and 2, respectively, compared to the low-yield cultures. Although specific productivity was lower in the high-yield cultures, this decrease was offset by the increased IVC, yielding higher titers in both cell lines. High-yield cultures showed a marked decrease in galactosylation, marked by a decrease in G1F glycans compared with the low-yield cultures, across both clones. Man5 glycans remained unchanged in clone 1 cultures, while a slight increase was observed in the high-yield clone 2 cultures. Metabolic analysis showed significant changes in glucose utilization in high-yield cultures with substantial decreases in specific glucose uptake and lactate yield, particularly for clone 2. Calculation of nucleotide sugar fluxes revealed that the increased utilization of UDP-N-acetylglucosamine and UDP-galactose for cellular glycosylation limited their availability for monoclonal antibody (mAb) glycosylation in high IVC, high-yield cultures, consistent with the observed changes in mAb glycans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.